Identification

Name
Bumetanide
Accession Number
DB00887  (APRD00294)
Type
Small Molecule
Groups
Approved
Description

A sulfamyl diuretic. [PubChem]

Structure
Thumb
Synonyms
  • 3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid
  • 3-Butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid
  • 3-Butylamino-4-phenoxy-5-sulfamoyl-benzoic acid
  • 3-Butylamino-4-phenoxy-5-sulfamoylbenzoic acid
  • Bumetanida
  • Bumetanidum
External IDs
a684051 / CS 380 / Ro 10-6338 / RO-10-6338
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BumexTablet0.5 mg/1OralGenentech, Inc.1983-02-282007-10-31Us
BumexTablet2 mg/1OralValidus Pharmaceuticals LLC1983-02-28Not applicableUs
BumexTablet2 mg/1OralGenentech, Inc.1983-02-282007-10-31Us
BumexTablet1 mg/1OralValidus Pharmaceuticals LLC1983-02-28Not applicableUs
BumexTablet1 mg/1OralGenentech, Inc.1983-02-282008-06-30Us
BumexTablet0.5 mg/1OralValidus Pharmaceuticals LLC1983-02-28Not applicableUs
Burinex - Tab 2mgTablet2 mgOralLeo Pharma1996-12-312004-07-23Canada
Burinex Tab 1mgTablet1 mgOralLeo Pharma1993-12-31Not applicableCanada
Burinex Tab 5mgTablet5 mgOralLeo Pharma1993-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BumetanideTablet1 mg/1OralPhysicians Total Care, Inc.2009-02-16Not applicableUs
BumetanideTablet2 mg/1OralZydus Pharmaceuticals (USA) Inc.2018-05-01Not applicableUs
BumetanideTablet1 mg/1OralAvera McKennan Hospital2015-09-282018-06-07Us
BumetanideTablet2 mg/1OralUpsher-Smith Laboratories, LLC2018-01-30Not applicableUs
BumetanideTablet1 mg/1OralNucare Pharmaceuticals, Inc.2015-10-15Not applicableUs
BumetanideTablet1 mg/1OralCardinal Health2011-04-292015-02-28Us
BumetanideTablet0.5 mg/1OralTeva2007-10-16Not applicableUs00093 4232 01 nlmimage10 2d2d16f8
BumetanideTablet2 mg/1OralUnit Dose Services2007-10-16Not applicableUs50436 423420180913 8702 1g2bco4
BumetanideTablet0.5 mg/1OralMylan Pharmaceuticals2010-01-012013-08-31Us
BumetanideInjection0.25 mg/1mLIntramuscular; IntravenousWest Ward Pharmaceutical2008-04-30Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
BumexBumetanide (1 mg/1)TabletOralPhysicians Total Care, Inc.1996-04-042011-05-31Us
International/Other Brands
Bumex (F. Hoffmann-La Roche Ltd.) / Burinex (F. Hoffmann-La Roche Ltd.) / Fordiuran (LEO Pharma A/S) / Lunetoron (Daiichi Sankyo)
Categories
UNII
0Y2S3XUQ5H
CAS number
28395-03-1
Weight
Average: 364.416
Monoisotopic: 364.10929245
Chemical Formula
C17H20N2O5S
InChI Key
MAEIEVLCKWDQJH-UHFFFAOYSA-N
InChI
InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)
IUPAC Name
3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid
SMILES
CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O

Pharmacology

Indication

For the treatment of edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome.

Associated Conditions
Pharmacodynamics

Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in patients in whom high doses of furosemide are ineffective. There is however no reason not to use bumetanide as a first choice drug. The main difference between the two substances is in bioavailability. It is said to be a more predictable diuretic, meaning that the predictable absorption is reflected in a more predictable effect. Bumetanide is 40 times more potent than furosemide (for patients with normal renal function).

Mechanism of action

Bumetanide interferes with renal cAMP and/or inhibits the sodium-potassium ATPase pump. Bumetanide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis.

TargetActionsOrganism
ASolute carrier family 12 member 1
inhibitor
Human
ASolute carrier family 12 member 2
inhibitor
Human
ASolute carrier family 12 member 4
inhibitor
Human
ASolute carrier family 12 member 5
inhibitor
Human
UCystic fibrosis transmembrane conductance regulator
antagonist
Human
Absorption

Bumetanide is completely absorbed (80%), and the absorption is not altered when taken with food. Bioavailability is almost complete.

Volume of distribution
Not Available
Protein binding

97%

Metabolism

45% is secreted unchanged. Urinary and biliary metabolites are formed by oxidation of the N-butyl side chain.

Route of elimination

Oral administration of carbon-14 labeled Bumex to human volunteers revealed that 81% of the administered radioactivity was excreted in the urine, 45% of it as unchanged drug. Biliary excretion of Bumex amounted to only 2% of the administered dose.

Half life

60-90 minutes

Clearance
  • 0.2 - 1.1 mL/min/kg [preterm and full-term neonates with respiratory disorders]
  • 2.17 mL/min/kg [neonates receiving bumetanide for volume overload]
  • 1.8 +/- 0.3 mL/min/kg [geriatric subjects]
  • 2.9 +/- 0.2 mL/min/kg [younger subjects]
Toxicity

Overdosage can lead to acute profound water loss, volume and electrolyte depletion, dehydration, reduction of blood volume and circulatory collapse with a possibility of vascular thrombosis and embolism. Electrolyte depletion may be manifested by weakness, dizziness, mental confusion, anorexia, lethargy, vomiting and cramps. Treatment consists of replacement of fluid and electrolyte losses by careful monitoring of the urine and electrolyte output and serum electrolyte levels.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Bumetanide Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Bumetanide.
AbacavirBumetanide may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbediterolThe risk or severity of hyperkalemia can be increased when Abediterol is combined with Bumetanide.
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Bumetanide.
AcebutololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Acebutolol.
AceclofenacThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Aceclofenac.
AcemetacinThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Acemetacin.
AcetaminophenAcetaminophen may decrease the excretion rate of Bumetanide which could result in a higher serum level.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be increased when used in combination with Bumetanide.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Acetyldigitoxin.
Food Interactions
  • Take with food to reduce irritation.

References

Synthesis Reference

Felt, P.W.; US. Patent 3,634,583; January 11, 1972; assigned to Lovens Kemiske Fabrik Produktionsaktieselskab, Denmark.

General References
Not Available
External Links
Human Metabolome Database
HMDB0015024
KEGG Drug
D00247
PubChem Compound
2471
PubChem Substance
46508147
ChemSpider
2377
BindingDB
25903
ChEBI
3213
ChEMBL
CHEMBL1072
Therapeutic Targets Database
DAP000361
PharmGKB
PA448682
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Bumetanide
ATC Codes
C03EB02 — Bumetanide and potassium-sparing agentsC03CB02 — Bumetanide and potassiumG01AE10 — Combinations of sulfonamidesC03CA02 — Bumetanide
AHFS Codes
  • 40:28.08 — Loop Diuretics
FDA label
Download (206 KB)
MSDS
Download (72.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentSeizures1
1CompletedTreatmentType 2 Diabetes Mellitus1
1, 2CompletedTreatmentNeonatal Convulsions1
1, 2RecruitingTreatmentUnresectable Hepatocellular Carcinoma1
2Not Yet RecruitingTreatmentAutism Spectrum Conditions/Disorders1
2TerminatedTreatmentHypokalemic Periodic Paralysis1
2WithdrawnTreatmentAutistic Disorder1
2, 3RecruitingHealth Services ResearchAcute Heart Failure (AHF)1
3CompletedTreatmentAutistics Children1
3RecruitingTreatmentAutism Spectrum Conditions/Disorders2
3WithdrawnTreatmentHeart Failure, Unspecified1
4CompletedTreatmentHeart Failure, Unspecified1
4RecruitingTreatmentCongestive Heart Failure (CHF) / Heart Failure, Unspecified1
Not AvailableRecruitingTreatmentCritical Care / Fluid Shifts1
Not AvailableRecruitingTreatmentKidney Insufficiency, Chronic1
Not AvailableTerminatedDiagnosticAcute Decompensated Heart Failure (ADHF)1

Pharmacoeconomics

Manufacturers
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Teva parenteral medicines inc
  • Validus pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Sandoz inc
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Amerisource Health Services Corp.
  • Baxter International Inc.
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Cardinal Health
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Eon Labs
  • F Hoffmann-La Roche Ltd.
  • Heartland Repack Services LLC
  • Hospira Inc.
  • Ivax Pharmaceuticals
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Neuman Distributors Inc.
  • Nucare Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Physicians Total Care Inc.
  • Sandhills Packaging Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Vangard Labs Inc.
Dosage forms
FormRouteStrength
InjectionIntramuscular; Intravenous0.25 mg/1mL
Injection, solutionIntramuscular; Intravenous0.25 mg/1mL
Injection, solutionIntravenous0.25 mg/1mL
TabletOral.5 mg/1
TabletOral0.5 mg/1
TabletOral2 mg/1
TabletOral1 mg/1
TabletOral2 mg
TabletOral1 mg
TabletOral5 mg
Prices
Unit descriptionCostUnit
Bumex 2 mg tablet1.65USD tablet
Bumetanide 2 mg tablet1.04USD tablet
Bumex 1 mg tablet0.98USD tablet
Bumex 0.5 mg tablet0.7USD tablet
Bumetanide 1 mg tablet0.51USD tablet
Bumetanide 0.5 mg tablet0.38USD tablet
Bumetanide 0.25 mg/ml vial0.25USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)230-231Felt, P.W.; US. Patent 3,634,583; January 11, 1972; assigned to Lovens Kemiske Fabrik Produktionsaktieselskab, Denmark.
water solubility>20 mg/mL (in base)Not Available
logP2.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0257 mg/mLALOGPS
logP3.44ALOGPS
logP2.42ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)4.69ChemAxon
pKa (Strongest Basic)2.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.72 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity95.78 m3·mol-1ChemAxon
Polarizability37.21 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9967
Blood Brain Barrier-0.6636
Caco-2 permeable-0.6492
P-glycoprotein substrateNon-substrate0.509
P-glycoprotein inhibitor INon-inhibitor0.8765
P-glycoprotein inhibitor IINon-inhibitor0.8103
Renal organic cation transporterNon-inhibitor0.8966
CYP450 2C9 substrateNon-substrate0.6368
CYP450 2D6 substrateNon-substrate0.7656
CYP450 3A4 substrateNon-substrate0.6059
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7344
Ames testNon AMES toxic0.6794
CarcinogenicityNon-carcinogens0.7294
BiodegradationNot ready biodegradable0.9837
Rat acute toxicity1.8148 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9319
hERG inhibition (predictor II)Non-inhibitor0.8591
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03di-0009000000-2a72173931dce5701622
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03di-0119000000-4abf1963718d72f73f59
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-001i-9351000000-b43658e112020008b9f9
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-001i-9100000000-4d303174266311856c28
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-001i-9000000000-2d120289f52c86515bea
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014i-0009000000-97827d479a3470c40d42
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-015c-0396000000-5edaaa0fcc7cd3681c24
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-000x-0980000000-0b360ca9bf4e58649db7
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-053s-0910000000-c5fc710abfdf5947bc62
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4j-0900000000-368c9661bc6dfd8a8d83
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-000x-0291000000-134f42a8645c2f1b9bc5
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0009000000-e4d18d4c63310d0528db
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000x-0390000000-abfea32acc207ff88b1f
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-053r-0930000000-cc33040126bfe7cb08fa
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a5a-0910000000-42b9627a1135073b6ce1
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0ars-0900000000-d22f5ff182cd71ced792
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00lu-0594000000-78579410f8f6799b400b
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00lu-1694000000-dbf4d76ea1a12ee57935
MS/MS Spectrum - , positiveLC-MS/MSsplash10-053s-2920000000-ecd6db66d16ce8f483b8

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylethers
Direct Parent
Diphenylethers
Alternative Parents
Aminobenzenesulfonamides / Diarylethers / Aminobenzoic acids / Benzenesulfonyl compounds / Benzoic acids / Phenylalkylamines / Aniline and substituted anilines / Phenoxy compounds / Phenol ethers / Benzoyl derivatives
show 9 more
Substituents
Diphenylether / Aminobenzenesulfonamide / Diaryl ether / Aminobenzoic acid / Aminobenzoic acid or derivatives / Benzenesulfonamide / Benzoic acid or derivatives / Benzenesulfonyl group / Benzoic acid / Phenoxy compound
show 27 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
sulfonamide, benzoic acids, amino acid (CHEBI:3213)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A1
Uniprot ID
Q13621
Uniprot Name
Solute carrier family 12 member 1
Molecular Weight
121449.13 Da
References
  1. Thakker RV: Chloride channels in renal disease. Adv Nephrol Necker Hosp. 1999;29:289-98. [PubMed:10561751]
  2. Karolyi L, Koch MC, Grzeschik KH, Seyberth HW: The molecular genetic approach to "Bartter's syndrome". J Mol Med (Berl). 1998 Apr;76(5):317-25. [PubMed:9587066]
  3. Thakker RV: The role of renal chloride channel mutations in kidney stone disease and nephrocalcinosis. Curr Opin Nephrol Hypertens. 1998 Jul;7(4):385-8. [PubMed:9690036]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  5. Long P, Mercer A, Begum R, Stephens GJ, Sihra TS, Jovanovic JN: Nerve Terminal GABAA Receptors Activate Ca2+/Calmodulin-dependent Signaling to Inhibit Voltage-gated Ca2+ Influx and Glutamate Release. J Biol Chem. 2009 Mar 27;284(13):8726-37. doi: 10.1074/jbc.M805322200. Epub 2009 Jan 13. [PubMed:19141616]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A2
Uniprot ID
P55011
Uniprot Name
Solute carrier family 12 member 2
Molecular Weight
131445.825 Da
References
  1. Panet R, Marcus M, Atlan H: Overexpression of the Na(+)/K(+)/Cl(-) cotransporter gene induces cell proliferation and phenotypic transformation in mouse fibroblasts. J Cell Physiol. 2000 Jan;182(1):109-18. [PubMed:10567922]
  2. Evans RL, Park K, Turner RJ, Watson GE, Nguyen HV, Dennett MR, Hand AR, Flagella M, Shull GE, Melvin JE: Severe impairment of salivation in Na+/K+/2Cl- cotransporter (NKCC1)-deficient mice. J Biol Chem. 2000 Sep 1;275(35):26720-6. [PubMed:10831596]
  3. Wall SM, Fischer MP, Mehta P, Hassell KA, Park SJ: Contribution of the Na+-K+-2Cl- cotransporter NKCC1 to Cl- secretion in rat OMCD. Am J Physiol Renal Physiol. 2001 May;280(5):F913-21. [PubMed:11292635]
  4. Akar F, Jiang G, Paul RJ, O'Neill WC: Contractile regulation of the Na(+)-K(+)-2Cl(-) cotransporter in vascular smooth muscle. Am J Physiol Cell Physiol. 2001 Aug;281(2):C579-84. [PubMed:11443057]
  5. Jiang G, Klein JD, O'Neill WC: Growth factors stimulate the Na-K-2Cl cotransporter NKCC1 through a novel Cl(-)-dependent mechanism. Am J Physiol Cell Physiol. 2001 Dec;281(6):C1948-53. [PubMed:11698253]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Protein kinase binding
Specific Function
Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May contribute to cell volume homeostasis in single cells. May be involved in the regulation of basolateral C...
Gene Name
SLC12A4
Uniprot ID
Q9UP95
Uniprot Name
Solute carrier family 12 member 4
Molecular Weight
120648.73 Da
References
  1. Jean-Xavier C, Pflieger JF, Liabeuf S, Vinay L: Inhibitory postsynaptic potentials in lumbar motoneurons remain depolarizing after neonatal spinal cord transection in the rat. J Neurophysiol. 2006 Nov;96(5):2274-81. Epub 2006 Jun 28. [PubMed:16807348]
  2. Reid KH, Guo SZ, Iyer VG: Agents which block potassium-chloride cotransport prevent sound-triggered seizures in post-ischemic audiogenic seizure-prone rats. Brain Res. 2000 May 2;864(1):134-7. [PubMed:10793196]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Protein kinase binding
Specific Function
Mediates electroneutral potassium-chloride cotransport in mature neurons. Transport occurs under isotonic conditions, but is activated 20-fold by cell swelling. Important for Cl(-) homeostasis in n...
Gene Name
SLC12A5
Uniprot ID
Q9H2X9
Uniprot Name
Solute carrier family 12 member 5
Molecular Weight
126182.49 Da
References
  1. Reid KH, Guo SZ, Iyer VG: Agents which block potassium-chloride cotransport prevent sound-triggered seizures in post-ischemic audiogenic seizure-prone rats. Brain Res. 2000 May 2;864(1):134-7. [PubMed:10793196]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Pdz domain binding
Specific Function
Involved in the transport of chloride ions. May regulate bicarbonate secretion and salvage in epithelial cells by regulating the SLC4A7 transporter. Can inhibit the chloride channel activity of ANO...
Gene Name
CFTR
Uniprot ID
P13569
Uniprot Name
Cystic fibrosis transmembrane conductance regulator
Molecular Weight
168139.895 Da
References
  1. Reddy MM, Quinton PM: Bumetanide blocks CFTR GCl in the native sweat duct. Am J Physiol. 1999 Jan;276(1 Pt 1):C231-7. [PubMed:9886939]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Cheng HF, Wang JL, Zhang MZ, McKanna JA, Harris RC: Role of p38 in the regulation of renal cortical cyclooxygenase-2 expression by extracellular chloride. J Clin Invest. 2000 Sep;106(5):681-8. [PubMed:10974021]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Virus receptor activity
Specific Function
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presenc...
Gene Name
SLC10A1
Uniprot ID
Q14973
Uniprot Name
Sodium/bile acid cotransporter
Molecular Weight
38118.64 Da
References
  1. Hagenbuch B, Stieger B, Foguet M, Lubbert H, Meier PJ: Functional expression cloning and characterization of the hepatocyte Na+/bile acid cotransport system. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10629-33. [PubMed:1961729]
  2. Platte HD, Honscha W, Schuh K, Petzinger E: Functional characterization of the hepatic sodium-dependent taurocholate transporter stably transfected into an immortalized liver-derived cell line and V79 fibroblasts. Eur J Cell Biol. 1996 May;70(1):54-60. [PubMed:8738419]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Curator comments
Substrate activity was investigated in vitro.
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Race JE, Grassl SM, Williams WJ, Holtzman EJ: Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun. 1999 Feb 16;255(2):508-14. [PubMed:10049739]
  2. Uwai Y, Saito H, Hashimoto Y, Inui KI: Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000 Oct;295(1):261-5. [PubMed:10991988]
  3. VanWert AL, Gionfriddo MR, Sweet DH: Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. Biopharm Drug Dispos. 2010 Jan;31(1):1-71. doi: 10.1002/bdd.693. [PubMed:19953504]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713]
  2. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000 Feb 11;275(6):4507-12. [PubMed:10660625]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name
SLC22A7
Uniprot ID
Q9Y694
Uniprot Name
Solute carrier family 22 member 7
Molecular Weight
60025.025 Da
References
  1. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, Endou H: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82. [PubMed:9650585]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Horz JA, Honscha W, Petzinger E: Bumetanide is not transported by the Ntcp or by the oatp: evidence for a third organic anion transporter in rat liver cells. Biochim Biophys Acta. 1996 Apr 19;1300(2):114-8. [PubMed:8652636]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2018 07:53